Inhibitors of Transforming Growth Factor Beta Receptor 1 (TGFβr1) May Enhance the Efficacy of Several Monoclonal Antibodies as Cancer Therapy
Author:
Affiliation:
1. Therachem Research Medilab, LLC, 100 Jade Park, Chelsea, Alabama 35043, United States
Publisher
American Chemical Society (ACS)
Subject
Organic Chemistry,Drug Discovery,Biochemistry
Link
https://pubs.acs.org/doi/pdf/10.1021/acsmedchemlett.2c00356
Reference6 articles.
1. Tumor in the Crossfire: Inhibiting TGF-β to Enhance Cancer Immunotherapy
2. TGF-Beta Type I Receptor (Alk5) Kinase Inhibitors in Oncology
3. Small Molecule Agents Targeting PD-1 Checkpoint Pathway for Cancer Immunotherapy: Mechanisms of Action and Other Considerations for Their Advanced Development
4. OX40 agonists for cancer treatment: a patent review
5. A Tumor-Localized Approach to Bypass Anti-4-1BB Immuno-Toxicity
Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. PF-06952229, a selective TGF-β-R1 inhibitor: preclinical development and a first-in-human, phase I, dose-escalation study in advanced solid tumors;ESMO Open;2024-09
2. A decade's overview of 2‐aminothiophenes and their fused analogs as promising anticancer agents;Archiv der Pharmazie;2024-03-05
3. Evaluation of the phytochemistry of Gymnostachyum febrifugum Benth. extract and its hepatoprotective activity using in vitro and in silico methods;Annals of Phytomedicine An International Journal;2023-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3